The Role of the Medicinal Chemist in the Drug Discovery Process: current status and future prospects By Dr Stevan W Djuric The need for the pharmaceutical industry to produce a constant stream of new NCEs has never been more paramount but with constantly changing R&D paradigms what is the role… Read More
Next Generation HIV Drugs move into late stage development By Dr Graham P. Allaway and Dr Jeffrey M. Jacobson There are currently 24 drugs approved for treating HIV infection. Of these, 23 are small molecule orally available drugs, or drug combinations, targeting the virus' reverse transcriptase and protease enzymes, targets… Read More
Advances in the imaging of biomolecules: the label-free intrinsic imaging approach By Dr Stuart Hassard, Dr Anthony D. Baxter and Dr John Hassard Many stages in the process of drug discovery require the separation, identification and analysis of biomolecules such as proteins, peptides and nucleic acids. Such analyses have traditionally… Read More
Engineering Success: Wyeth redefines its research & development organisation By Dr Robert R. Ruffolo, Jr In an era of unprecedented productivity challenges, rising regulatory constraints and ever increasing costs, the need to be innovative, productive and efficient in all R&D departments has never been greater. We discuss how and why… Read More
Applying the semantic web to drug discovery and development By Dr Eric Neumann There is much happening in drug development these days: new target classes, increasing costs, new forms of high throughput screening, and the promise of personalised medicine. But of all the issues, the one that now takes centre… Read More
Redefining Drug Discovery Informatics By Bryan S. Koontz As the pharmaceutical industry changes in response to unprecedented challenges, information technology supporting the drug discovery process must evolve and be redefined in order to improve research productivity and success rates. Improvements to traditional computational chemistry applications will continue to provide incremental… Read More
By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. So no matter that the umbrella was… Read More
Nanotechnology approaches to solving the problems of poorly water-soluble drugs By Dr Roghieh Saffie-Siebert, Dr Jill Ogden and Dr Mark Parry-Billings Traditionally, almost half of new molecular entities identified by pharmaceutical industry screening programmes have failed to be developed because of poor water-solubility, which makes their formulation difficult or even… Read More
Creating a productive R&D culture By Janet White Increasing R&D productivity is the current mantra of pharmaceutical industry executives. The promise of new technologies and process improvements has been extensively discussed. However, fundamental culture change within research organisations remains the final unexplored frontier to increased productivity. This article introduces the… Read More
How a new compliance agenda is changing the face of the drug discovery industry By Dr Doug Dean and Frances Bruttin Safe and effective drug products for the 21st century can be developed if, and only if, firms understand the mechanism of action of their products, and they are able… Read More
The search for validated biomarkers in the face of biosystems complexity By Professor Ian Humphery-Smith and Will Dracup As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets few of which have been well validated. Indeed, apart from… Read More
Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted… Read More
Patent Pools as a Solution to the licensing problems of diagnostic genetics - United States and European perspectives By Dr Jorge A. Goldstein, Dr Ted J. Ebersole, Marvin C. Guthrie, Annette A. Hirschfeld and Bart J. van den Broek Advances in diagnostic genetic testing have resulted in the ability to… Read More
COX-2 Inhibitor Toxicity - Warning shot over pharma's bow By Dr Mark Schena and Dr William Greene Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable… Read More
The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines By Professor Jan Tornell The pharmaceutical industry is faced with the challenge to deliver truly novel medicines to a market under financial pressure when pharmaceutical R&D becomes increasingly difficult and complex. This review will mainly focus on… Read More
Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved productivity and limited drug pipeline growth is… Read More